Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03205150 · ClinicalTrials.gov registry record · Phase 2
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
A Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 15
- Study locations
NCT03205150 is a Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 107 participants. The trial reports 15 study locations across 7 states.
The verdict
NCT03205150, a Phase 2 study of Obese Patients With Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LIK066
Study Locations (15)
Other
- Novartis Investigative Site - Buenos Aires
- Novartis Investigative Site - Haifa
- Novartis Investigative Site - Ramat Gan
- Novartis Investigative Site - Tel Aviv
- Novartis Investigative Site - Leiden
- Novartis Investigative Site - Saint Petersburg
- Novartis Investigative Site - Chiayi City
- Novartis Investigative Site - Tainan
- Novartis Investigative Site - Bangkok
Louisiana
- Novartis Investigative Site - Baton Rouge
Missouri
- Novartis Investigative Site - St Louis
Tennessee
- Novartis Investigative Site - Knoxville
Texas
- Novartis Investigative Site - Live Oak
Buenos Aires
- Novartis Investigative Site - CABA
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2019-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03205150
The ClinicalTrials.gov registry entry for NCT03205150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obese Patients With Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03205150 reports 15 study locations spanning 7 distinct geographic areas - top geographies include Other, Louisiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT03205150 about?
NCT03205150 is a clinical study titled "Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients". The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
What is the current status of trial NCT03205150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2017-10-04. Estimated completion is 2019-11-14.
What conditions does trial NCT03205150 study?
This clinical trial studies the following conditions: Obese Patients With Non-alcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT03205150?
The interventions under investigation include: Placebo (DRUG), LIK066 (DRUG).
Who is sponsoring clinical trial NCT03205150?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03205150 being conducted?
This trial has 15 study locations across Louisiana, Missouri, Tennessee, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.